Brought to you by 
Oncology firms Oncternal and Tokalas merge
14 Sep 2020
Executive Summary
Cancer drug development firms Oncternal Therapeutics Inc. and Tokalas Inc. have merged into one entity which will carry the Oncternal name, and be led by Tokalas CEO Dr. James Breitmeyer. Financial details were not disclosed.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Oncology firms Oncternal and Tokalas merge
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice